按基金排序
10/25/21

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

10/19/21

Castle Biosciences收购cernostic

8/22/21

太阳能在乔治亚州蓬勃发展,那里没有强制要求

7/19/21

Mindera™公布了一项针对银屑病治疗的精准药物测试的经济评估

6/17/21

PhaseBio宣布与Alfasigma S签订欧洲许可协议.p.A用于Bentracimab的商业化

6/15/21

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

5/12/21

ALSS获得700万美元B系列资金,用于将家禽行业的新型疫苗交付系统商业化

5/11/21

Mindera A-2融资1200万美元

4/30/21

十亿美元的农场帮手:Silicon RANCH是如何成为本土巨头的

4/27/21

Castle Biosciences签署最终协议收购Myriad myPath®实验室

3/2/21

G1和勃林格英格尔海姆COSELA™(trilaciclib)上市, the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

2/12/21

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

12/22/20

2021年最值得买入的21只股票

12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12/15/20

Silicon Ranch与现有股东完成2.25亿美元股权融资

12/9/20

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

11/2/20

Castle Biosciences公司宣布,DecisionDx DiffDx-Melanoma正式上市

10/8/20

Castle Biosciences宣布扩大皮肤黑色素瘤的医疗保险覆盖范围

10/6/20

作为Bentracimab逆it全球3期试验的一部分,PhaseBio首先在加拿大给患者提供剂量

9/2/20

Castle Biosciences宣布DecisionDx-SCC上市

7/27/20

Mindera公司宣布任命小布什. Mahaffey担任总裁兼首席执行官

6/24/20

城堡生物科学宣布定价为74美元.2亿普通股公开发行

5/27/20

PhaseBio启动临床试验,评估PB1046作为COVID-19住院患者的治疗

4/13/20

Orig3n获得FDA紧急使用授权(EUA)用于冠状病毒2019测试

1/13/20

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

1/10/20

PhaseBio宣布与SFJ Pharmaceuticals®就pb2452进行融资和联合开发合作

11/21/19

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

11/19/19

Silicon Ranch签约Facebook在乔治亚州的107兆瓦太阳能项目

10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

10/15/19

PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

9/4/19

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

8/14/19

PhaseBio宣布收到与FDA的阶段1结束会议的会议记录,并对单个, 非随机3期试验支持PB2452的BLA提交

7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

6/26/19

Silicon Ranch推出再生能源™

6/18/19

G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER

6/17/19

PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects

4/29/19

G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020

4/8/19

PhaseBio宣布普通股公开发行结束

4/8/19

PhaseBio获得突破性治疗称号

3/19/19

应用LifeSciences & Systems宣布结束其800万美元的A轮股权融资

3/17/19

《彩乐园2》刊登了一期生物一期临床试验的全部结果

3/6/19

独立展望出版物, 多中心研究加强了黑色素瘤试验复发风险预测的准确性

2/20/19

Clearside收到FDA接受XIPERE NDA备案的通知

2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

12/6/18

Castle Biosciences宣布任命基因组健康首席财务官G. Bradley Cole加入董事会

12/5/18

硅谷农场将为Facebook在乔治亚州的数据中心提供电力

10/18/18

Castle Biosciences宣布皮肤黑色素瘤的decisiondx黑色素瘤测试的医疗保险覆盖范围

8/27/18

PhaseBio在D轮融资中获得3400万美元

7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

6/28/18

APPELLO完成10美元.500万美元的a轮融资由deerfield management和mountain group partners牵头

5/31/18

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

5/23/18

歌公司. 获得Aspire健康

4/16/18

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

3/28/18

Castle Biosciences宣布将DecisionDx-UM预后测试纳入葡萄膜黑色素瘤的新NCCN指南

3/15/18

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

3/5/18

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

1/22/18

壳牌收购美国太阳能开发公司硅牧场的主要股份

1/22/18

壳牌收购硅牧场公司

1/4/18

亚博科技加速器首次投资新型杀菌剂公司Boragen Inc.该公司的A轮融资为1,000万美元

1/4/18

亚博加速器在天际线兽医制药公司获得500万美元的A轮融资,成为彩乐园2行业的首笔投资

12/18/17

G1 Therapeutics加入Nasdaq生物科技指数

9/18/17

G1疗法加入罗素2000®,3000®和Microcap®指数

7/31/17

Myomo公司. 获得CE认证MyoPro®

7/13/17

G1 Therapeutics任命Andrew Witty爵士为董事会成员

6/27/17

生物技术公司ORIG3N获得2000万美元

6/9/17

Myomo公司. 完成历史性的首次公开发行

5/30/17

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

5/25/17

MolDX未来局部覆盖率的确定:DecisionDxUM(葡萄膜黑色素瘤)(L37033)

5/16/17

G1公司宣布首次公开募股定价

4/18/17

NeuroTronik宣布23美元.100万B轮优先股融资

3/29/17

G1 Therapeutics在2017年美国癌症研究协会年会上发表演讲

1/10/17

G1公司在乳腺癌领域启动了三个药物开发项目

12/5/16

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

11/2/16

AgTech Accelerator Corporation Announces the Addition of 彩乐园2 Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

9/21/16

NuSirt生物制药和OWL代谢组学合作推进NASH /非酒精性脂肪性肝炎的治疗

6/1/16

Clearside生物医学公司. 宣布首次公开发行的定价

5/11/16

G1公司获得4700万美元C轮融资

4/27/16

密西西比电力,硅牧场破土动工新的太阳能设施

4/27/16

Partners Group对Silicon Ranch Corporation投资1亿美元, 彩乐园2的开发人员, 太阳能发电设施的拥有者和经营者

4/26/16

Clearside生物医学公司. 宣布阳性的初步2期结果与视网膜静脉阻塞的黄斑水肿患者

4/15/16

TVA和美国国家安全局中南部大型太阳能农场的硅牧场彩乐园2

2/1/16

一家本地创业公司正在建设世界上最大的iPS干细胞银行

1/26/16

临床试验结果显示NuSirt技术与二甲双胍在2型糖尿病患者中的协同作用

12/14/15

Clearside生物医学公司. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration

12/10/15

NuSirt生物制药公司获得FDA非酒精性脂肪肝治疗快速通道指定

12/3/15

Clearside生物医学公司. 完成2000万美元C轮融资

12/1/15

绿色电力EMC和硅牧场奉献20兆瓦乔治亚太阳能设施

1/15/15

Clearside生物医学公司. 启动治疗非感染性葡萄膜炎黄斑水肿的二期临床试验

7/7/14

NuSirt生物制药技术在美国糖尿病协会科学会议上发表